Ceretas Reports $1.63 Million FY26 Loss on $1.28 Million Revenue, Completes $8 Million IPO

• FY26 revenue surged 21,615% to $1.28 million, driven by government grants
• Net loss widened to $1.63 million amid ramped-up R&D and corporate costs
• Successful $8 million IPO completed post-year end to fund Phase 2 trial and device development
• Phase 1 trial published showing safety and reduction in behavioural symptoms
• Company acquired full intellectual property rights from UniQuest post-IPO

Grant-Fuelled Revenue Masks Rising Losses

Ceretas Limited (ASX:CTS) reported a dramatic jump in revenue to $1.28 million for the year ended 30 June 2026, up 21,615% from just $5,908 in its prior period. This surge was almost entirely due to government grant income, notably a $2.39 million CUREator+ Dementia and Cognitive Decline grant awarded in July 2025. Despite this, the company’s net loss ballooned by 787% to $1.63 million, reflecting increased research and development expenses and higher administrative costs as Ceretas transitioned from an early-stage startup to a clinical-stage medtech company.

Clinical Progress and IPO Milestones

FY26 marked Ceretas’ first full financial year since incorporation in October 2024 and included key operational milestones. The company published first-in-human Phase 1 results in December 2025, demonstrating that focused ultrasound neuromodulation was safe, feasible, and tolerable in 12 Alzheimer’s patients, with 10 showing statistically significant reductions in behavioural symptoms. Ethics approval was secured in May 2026 for the CERE-CALM Phase 2 trial, a randomised sham-controlled study targeting behavioural and psychological symptoms of dementia, positioning Ceretas to commence patient recruitment imminently.

Subsequent to the reporting period, Ceretas completed a successful initial public offering (IPO) in July 2026, raising $8 million before costs by issuing 32 million shares at $0.25 each. The listing on the ASX with a market capitalisation of $17.8 million provides a vital capital platform to fund clinical trials, next-generation device development, and regulatory engagement, including a planned pre-submission meeting with the US FDA.

Exclusive Intellectual Property Secured

The company holds exclusive rights to its core ultrasound technology, licensed from UniQuest and developed over a decade at the University of Queensland’s Queensland Brain Institute. In July 2026, Ceretas exercised its option to acquire full legal title to the intellectual property portfolio, issuing 1 million shares to UniQuest as consideration. This move replaced the previous licence agreement with a direct ownership structure, while granting UniQuest and the university a perpetual royalty-free licence for non-commercial research.

Financial Position and Executive Incentives

At 30 June 2026, Ceretas held $1.19 million in cash and net assets of $1.33 million, excluding the $8 million IPO proceeds received after year end. The company remains pre-revenue, with no operating income expected until regulatory approval and commercial launch, which are likely several years away. Operating expenses are set to increase as clinical trials ramp up.

Key executives and directors have been granted substantial equity incentives aligned with strategic milestones, including 4.3 million incentive options and 2.5 million performance rights. However, management assessed the probability of vesting for these performance rights as zero at year end, reflecting the early stage of development and regulatory uncertainty.

Challenges Ahead for Clinical and Regulatory Success

Ceretas faces significant challenges typical of clinical-stage medtech companies: securing successful Phase 2 trial outcomes, navigating complex regulatory pathways with the FDA, and raising further capital for pivotal Phase 3 studies. The company’s near-term cash runway is supported by IPO proceeds and grant funding, but it will remain loss-making and dependent on external financing until commercialisation. The company’s unique focused ultrasound platform, targeting neuromodulation and blood-brain barrier opening for Alzheimer’s, offers a novel approach in a field with limited treatment options.

Investors should watch closely for recruitment progress in the CERE-CALM trial, preclinical data on the blood-brain barrier opening program, and regulatory feedback from the FDA, which will shape Ceretas’ capital needs and commercial prospects in the coming years.

Bottom Line?

Ceretas has secured vital funding and IP ownership to advance its Alzheimer’s ultrasound device, but clinical and regulatory hurdles remain critical for its future viability.

Questions in the middle?

• How will recruitment challenges in Alzheimer’s patient populations impact the timing of Phase 2 trial results?
• What regulatory classification will the FDA assign to Ceretas’ device, and how might this affect approval timelines?
• To what extent will the company need to raise additional capital post-Phase 2 to fund pivotal trials and commercialisation?